Reference Interval:
| Test Number
| Components
| Reference Interval
| | | Alpha Fetoprotein Total
| 0-15 ng/mL
| | | Alpha Fetoprotein L3 Percent
| 0-9.9 percent
| | 0081312 | Des-gamma-carboxy Prothrombin
| By report
|
|
| Interpretive Data: |
The µTASWako method is used. Results obtained with different assay methods or kits cannot be used interchangeably.
The AFP-L3 Percent assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases.
Patients with elevated serum AFP-L3 percent should be more intensely evaluated for evidence of hepatocellular carcinoma since elevated values have been shown to be associated with a seven-fold increase in the risk for developing hepatocellular carcinoma within 21 months. For pregnant females, the result is not interpretable as a tumor marker.
The des-gamma-carboxy prothrombin (DCP) assay is intended as a risk assessment for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk for developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma.
|
| CPT Code(s): |
82107 AFP L3; 83951 DCP
|
Cross References: |
Alpha Fetoprotein, Total & L3 Percent Tumor Marker (Hepatocellular Carcinoma Tumor Marker Panel), Des-Gamma-Carboxy Prothrombin Tumor Marker (Hepatocellular Carcinoma Tumor Marker Panel) |